The Boosting Potential of Bacteria in Cancer Immunotherapy

David C Binder; Derek A Wainwright

doi:10.1016/j.molmed.2017.05.008

The Boosting Potential of Bacteria in Cancer Immunotherapy

Trends Mol Med. 2017 Jul;23(7):580-582. doi: 10.1016/j.molmed.2017.05.008. Epub 2017 Jun 2.

Authors

David C Binder¹, Derek A Wainwright²

Affiliations

¹ Department of Radiation Oncology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
² Department of Neurological Surgery, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Department of Microbiology-Immunology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Department of Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA. Electronic address: derekwainwright@northwestern.edu.

Abstract

Salmonella Typhimurium, engineered to express flagellin B, recently demonstrated unprecedented tumor control through a TLR-dependent mechanism. Here, we review new observations that support the potential of utilizing modified bacteria to enhance antitumor immunity. We also discuss the implications of these findings for clinical applications, including immune checkpoint blockade therapies.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Animals
Flagellin / genetics
Flagellin / immunology*
Flagellin / therapeutic use*
Humans
Immunotherapy / methods*
Neoplasms / immunology
Neoplasms / therapy*
Salmonella typhimurium / genetics
Salmonella typhimurium / immunology*
Toll-Like Receptors / genetics
Toll-Like Receptors / immunology

Substances

Toll-Like Receptors
Flagellin
flaB flagellin

Abstract

Publication types

MeSH terms

Substances

Grants and funding